KR20160078647A - Novel MELK shRNA suppressing MELK expression, and use thereof - Google Patents

Abstract

The present invention relates to MELK shRNA having a novel particular sequence, and a medical composition comprising the same as an active component. The composition can be used wisely in preventing and treating cancers as the MELK shRNA having a novel particular sequence exhibits an excellent gene expression inhibitory effect compared to conventional MELK shRNA and effectively inhibits the expression of MELK in various types of cancer cells.

Description

Novel MELK shRNA inhibiting MELK expression and its use {Novel MELK shRNA suppressing MELK expression, and use thereof}

The present invention relates to an shRNA having a novel base sequence inhibiting MELK (Maternal Embryonic Leucine zipper Kinase) expression and a pharmaceutical composition for preventing and treating cancer containing the shRNA as an active ingredient.

MELK (Maternal Embryonic Leucine zipper Kinase) belongs to the snf1 / AMPK family involved in mammalian embryonic development (Heyer BS et al., Dev Dyn 1999 Aug 215 (4): 344-51), by adenosine monophosphate Activated serine / threonine kinase (serine / threonine kinase). MELK was first found in embryos of the African claw frog (Xenopus) and is known to maximize its amount or activation during the mitotic phase of the cell cycle. This phenomenon has also been confirmed in vertebrate cells (Blot J. et al., Dev. Biol. 2002, 241 (2): 327-338; Davezac N. et al., Oncogene, 2002, 21: 7630-7641). As a protein that is phosphorylated by MELK, CDC25 is known to be involved in the cell cycle (Dmitry V. et al., Nat. Cell Biol., 2003, 5: 545-551), which phosphorylates the transcription protein ZPR9 (Hyun-A Seoung et al., J. Biol. Chem., 2003, 278: 9655-9662). Recently, the expression of MELK was found to be increased in the tissues of patients with breast cancer or adenocarcinoma, and inhibition of MELK expression alone was found to inhibit the growth of cancer cells (Ichiro Nakano et al., J. Neurosci. Res., 2008, 86: 48-60; Haiyoung Jung et al., J. Biol. Chem., 2008, 283: 34541-34553).

In tumor cell lines, MELK is known to function as a cell cycle regulator and is known to play an important role in a variety of cancers. Thus, MELK is involved in stem cell regeneration, cell cycle and pre-mRNA splicing, and its gene and protein information is registered in the NCBI (National Center for Biotechnology Information) (NM_014791, NP_055606). This gene has been shown to be useful in stem cell regeneration (Nakano I et al., J Cell Biol. 2005 Aug 1, 170 (3): 413-27), cell-cycle progression (Blot J et al. MRNA splicing (Vulsteke V et al., J Biol. J. Immunol. 2002, 31 (2): 327-38; Seong HA et al., IoChem J. 2002 Feb 1, 361 (Pt 3): 597-604) Chem. 2004 Mar 5, 279 (10): 8642-8647). In addition, MELK has recently been shown to be up-regulated in breast cancer through analysis of gene expression profiles using a genomic-wide cDNA microarray containing 23,040 genes (Lin ML et al., Breast Cancer Res. 2007; 9 (1 ): R17, WO2006 / 016525, WO2008 / 023841). In addition, MELK is upregulated in several types of cancer cells, such as lung, bladder, lymphoma and cervical cancer cells (WO2004 / 031413, WO2007 / 013665, and WO2006 / 085684). That is, MELK has not been expressed in normal organs (heart, liver, lung and kidney), and has been overexpressed to a remarkably high level in the majority of breast cancer and cell lines (WO2006 / 016525). Furthermore, inhibition of MELK expression by siRNA was shown to significantly inhibit the growth of human breast cancer cells. In addition, MELK is overexpressed in brain cancer, and such overexpression has a negative impact on the prognosis of cancer patients. Therefore, if the expression of MELK can be inhibited, it may be possible to treat brain cancer.

Many of the cancer suppressants or anticancer drugs used in the past have been used as chemotherapeutic agents to temporarily control the symptoms and symptoms of cancer and prolong the life span. Recently, cancer inhibitors have been developed in order to minimize the adverse effects of cancer inhibitors on normal cells by targeting proteins or genes existing in specific cancer cells. Nevertheless, due to the various types of cancer-causing mechanisms, there is a lack of effective anticancer agents and resistance to anticancer drugs has not been solved. Many studies have been conducted to solve these problems, and shRNAs designed to inhibit gene expression of MELK have been designed. However, the previously reported shRNAs showed that the inhibitory effect on MELK protein expression was too small.

Therefore, the present inventors have made efforts to discover shRNAs that are superior to the previously reported shRNAs in suppressing the expression of MELK protein, and as a result, it has been confirmed that the shRNA having a novel specific sequence efficiently reduces MELK expression in various cancer cells, Completed.

An object of the present invention is to provide an shRNA which inhibits MELK (Maternal Embryonic Leucine zipper Kinase) expression having the nucleotide sequence shown in SEQ ID NOS: 2 to 16.

Another object of the present invention is to provide a vector comprising said shRNA.

It is still another object of the present invention to provide a pharmaceutical composition for preventing and treating cancer comprising the shRNA and the vector as an active ingredient, and a health functional food for improvement.

In order to achieve the above object, the present invention provides an shRNA inhibiting MELK expression having the nucleotide sequence of SEQ ID NOS: 2 to 16.

The present invention also provides a vector comprising the shRNA.

In addition, the present invention provides a pharmaceutical composition for preventing and treating cancer comprising the shRNA and the vector as an active ingredient, and a health functional food for improvement.

The MELK shRNA having the novel specific sequence of the present invention is superior to the known MELK shRNA in gene expression suppressing effect and effectively inhibits the expression of MELK in various cancer cells. Therefore, the pharmaceutical composition containing the MELK shRNA as an active ingredient can be used for the treatment of brain cancer, Breast cancer, stomach cancer, colon cancer and the like.

1 is a diagram showing a MELK base sequence.
FIG. 2 shows the result of Western blotting using MELK antibody after knockdown in Hela cells.
FIG. 3 shows the result of Western blotting using MELK antibody after lacking the novel 5, 9 and 12 shRNAs in A498 cells, A549 cells or SK-OV-3 cells.
FIG. 4 shows the result of Western blotting using MELK antibody after deficiency of existing shRNA (MELK1, MELK2, MELK3) in A498 cells, A549 cells or SK-OV-3 cells.

Hereinafter, the present invention will be described in detail.

The present invention provides an shRNA that inhibits MELK (Maternal Embryonic Leucine zipper Kinase) expression having the nucleotide sequences shown in SEQ ID NOS: 2 to 16. The MELK is described in SEQ ID NO: 1.

The shRNA (short hairpin RNA) has a hairpin structure in which the double-stranded RNA portions forming the pair of RNAs are not completely paired but form a stem-loop structure. The double- (Not corresponding to a corresponding base), a bulge (no base corresponding to one of the chains), and the like. The total length is 10 to 80 bases, preferably 15 to 60 bases, more preferably 20 to 40 bases. In addition, the loop region has no special significance in the sequence, and it is enough to have about 3-10 bases in order to connect the sense sequence and the antisense sequence at appropriate intervals. Examples of conventional shRNA loop regions are as follows: AUG (Sui et al., Proc. Natl Acad Sci USA 99 (8): 5515-5520, 2002), CCC, CCACC or CCACACC (Nature et al., Nature Biotechnology 20: 505-508, 2002), UUCG (Lee et al., Nature Biotechnology 20: 500-505), CTCGAG, AAGCUU (Editors of Nature Cell Biology Whither RNAi, Nat Cell Biol. USA 99 (9): 6047-6052, 2002) and TTGATATCCG (default spacer at www.genscript.com).

In addition, the present invention provides a vector comprising an shRNA that inhibits MELK (Maternal Embryonic Leucine zipper Kinase) expression having the nucleotide sequences of SEQ ID NOS: 2 to 16 above. The vector consists of linear DNA, plasmid DNA and recombinant viral vector.

The plasmid is annotated as a generic term for DNA molecules other than a chromosome that can replicate in a cell of a bacterium and can grow independently. Plasmids are not essential for the survival of bacteria, and they can also be transferred into other species' cells. Therefore, plasmids in bacteria are taken out of the cells using this property, cut into restriction enzymes, inserted into necessary genes, Use recombinant DNA technology to culture.

The recombinant virus may be selected from the group consisting of adenovirus, adeno-associated virus, retrovirus, herpes simplex virus and lentivirus.

Adenoviridae are medium size viruses with a size of 90-100 nm. They have no hulls and are in the form of a tetrahedron, and have double helix-shaped DNA. Adenovirus accounts for 5% to 10% of upper respiratory tract infections in children, and adults are also infected.

The adeno-associated virus is a single-stranded DNA virus belonging to the parvovirus and can not be cloned alone. It can be used in combination with a helper virus such as adenovirus, vaccinia, or herpesvirus It is a defective virus that can replicate and multiply when infected. When the helper virus is absent, the adenovirus viral genome is inserted into a specific region of the chromosome 19 of the human cell and remains in a latent state. When the helper virus is infected, replication and replication are possible. The adenovirus viral genome is a 4681 bp DNA with 145 bp of ITR on both ends, which is the minimum sequence required for replication, packaging and rescue. Within the ITR, there are two ORFs, the rep required for replication, and the cap gene coding for the structural protein. Adeno-associated virus can be latently infected in human cells, so that insertion into the chromosome does not cause any change in cell growth, efficiently infects various cells, and does not induce an immune response like adenovirus. The first recombinant adeno-associated viral vector may be prepared by removing the cap gene and inserting the foreign gene, and more preferably the rep gene and the cap gene may be replaced with a foreign gene.

The retrovirus is a series of viruses that are transfected into the chromosome of the host cell by converting the RNA genome into DNA in infected cells. To date, retroviral vectors based on Moloney Murine Leukemia Virus (MoMLV) It is most widely used in clinical trials. The retrovirus particle has a structure in which the protein core containing two strands of RNA is surrounded by the lipid outer membrane. Retroviruses are initiated by the binding of the outer membrane protein to specific receptors on the cell surface. In the case of the ecotropic outer membrane that can infect animal cells, the receptor is a cationic amino acid transporter, and the MoMLV amphotropic outer membrane The receptor is known as the phosphate transporter (Ram-1). The virus is introduced into the cell by the fusion between the virus and the cell membrane or the cell absorbing action, and the RNA of the virus is converted into DNA by the reverse transcription process and is transferred to the nucleus. Most retroviruses require mitosis and subsequent destruction of the nuclear envelope in order for the DNA to enter the nuclide, where DNA is inserted into the chromosome to form provirus. The gag, pol, and env gene products are synthesized from the RNA transcribed from the inserted provirus, and they produce viral particles by packaging only genomic viral RNA.

The lentivirus vector is a kind of retrovirus, and unlike general retroviruses, it is developed as a gene transfer vector because of its ability to infect not only dividing cells but also cells that have stopped growing or differentiated cells. An example is HIV, which includes six accessory genes in addition to gag, pol, and env. HIV vectors with some accessary genes removed can be infected with a wide range of cells such as brain, liver, and muscle cells in animal tests when pseudotyped with VSV outer membrane protein, and can induce continuous gene expression for more than 6 months.

In a specific embodiment of the invention, a sequence candidate is provided by entering the MELK sequence (SEQ ID NO: 1) (see FIG. 1) into Invitrogen (see Table 1) ) And a reverse primer (see Table 3). 100 pmole / μl of the forward primer and the reverse primer were annealed, and the annealed primer was inserted into the pLKO.1 vector digested with AgeI and EcoRI. 293T cells were transfected with the above three vectors to obtain lentivirus. The obtained medium was infected with cervical cancer cells (HeLa), kidney cancer cells (A498), lung cancer cells (A549) or ovarian cancer cells (SK-OV-3), and surviving cells were selected with puromycin The cell lysate was collected and the expression of MELK protein was inhibited by Western blotting (see FIGS. 2 and 3). Furthermore, it was confirmed that the MELK shRNA gene of the present invention was superior to the conventional MELK shRNAs (MELK1, MELK2, and MELK3) in suppressing the expression thereof (see FIG. 4).

Therefore, the MELK shRNA of the present invention is superior to the known MELK shRNA in gene expression inhibiting effect and effectively inhibits the expression of MELK in various cancer cells, and thus can be effectively used for prevention or treatment of cancer.

The present invention provides a pharmaceutical composition for preventing and treating cancer comprising the above shRNA and a vector as an effective ingredient.

Wherein the cancer is selected from the group consisting of brain cancer, gastric cancer, breast cancer, colon cancer, pancreatic cancer and liver cancer, bladder cancer, breast cancer, cervical cancer, cholangiocellular carcinoma, chronic myelogenous leukemia (CML), colon cancer, endometriosis, (NSCLC), lymphoma, osteosarcoma, ovarian cancer, pancreatic cancer, prostate cancer, renal carcinoma and small cell lung cancer.

Therefore, the MELK shRNA of the present invention is more effective than the conventional MELK shRNA in inhibiting gene expression and effectively suppresses the expression of MELK in various cancer cells, and thus can be used as an effective ingredient of a pharmaceutical composition for cancer prevention or treatment.

As used herein, the term " treatment " refers to the prevention of a disease or disease associated with a tumor as a result of prevention of tumor cell formation, inhibition of a disease or disease associated with tumor upon removal of tumor cells, and removal of tumor cells. Thus, as used herein, the term " therapeutically effective amount " means an amount sufficient to achieve the above pharmacological effect.

The pharmaceutically acceptable carriers to be included in the composition of the present invention are those conventionally used in the present invention and include lactose, dextrose, sucrose, sorbitol, mannitol, starch, acacia rubber, calcium phosphate, alginate, gelatin, calcium silicate , Microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, methylcellulose, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil, no. The pharmaceutical composition of the present invention may further contain a lubricant, a wetting agent, a sweetening agent, a flavoring agent, an emulsifying agent, a suspending agent, a preservative, etc., in addition to the above components.

The pharmaceutical composition of the present invention is preferably parenteral, and can be administered, for example, by intravenous administration, intraperitoneal administration, intratumoral administration, intramuscular administration, subcutaneous administration, or local administration. In case of intraperitoneal administration of ovarian cancer and administration in the context of liver cancer, it can be administered by injection. In the case of breast cancer, it can be administered by direct injection into the tumor mass. In the case of colon cancer, In the case of bladder cancer, it can be injected directly into the catheter.

The appropriate dosage of the pharmaceutical composition of the present invention varies depending on factors such as the formulation method, the manner of administration, the age, body weight, sex, severity of disease symptoms, food, administration time, route of administration, excretion rate and responsiveness of the patient Ordinarily skilled physicians can easily determine and prescribe dosages effective for the desired treatment. Generally, the pharmaceutical composition of the present invention contains 1 x 10 ⁵ - 1 x 10 ¹⁵ PFU / ml of recombinant virus, and usually 1 x 10 ¹⁰ PFU is injected every other day for two weeks.

The pharmaceutical composition of the present invention may be formulated into pharmaceutically acceptable carriers and / or excipients according to a method which can be easily carried out by those skilled in the art, Or by intrusion into a multi-dose container. The formulations may be in the form of solutions, suspensions or emulsions in oils or aqueous media, or in the form of excipients, powders, granules, tablets or capsules, and may additionally contain dispersing or stabilizing agents.

In addition, the present invention provides a health functional food for cancer prevention and improvement comprising the shRNA and the vector as effective ingredients.

Wherein the cancer is selected from the group consisting of brain cancer, gastric cancer, breast cancer, colon cancer, pancreatic cancer and liver cancer, bladder cancer, breast cancer, cervical cancer, cholangiocellular carcinoma, chronic myelogenous leukemia (CML), colon cancer, endometriosis, (NSCLC), lymphoma, osteosarcoma, ovarian cancer, pancreatic cancer, prostate cancer, renal carcinoma and small cell lung cancer.

Therefore, the MELK shRNA of the present invention is superior to the known MELK shRNAs in gene expression suppressing effect and effectively suppresses the expression of MELK in various cancer cells, and thus can be used as an effective ingredient of a health functional food for cancer prevention or improvement.

In order to use the MELK shRNA of the present invention as an active ingredient for the prevention and improvement of cancer, the health functional food can be prepared by various methods known in the field of food science or pharmaceuticals, and can be prepared by itself or as a pharmaceutically acceptable carrier, , Diluents, and the like, and can be manufactured into any food form that can be ingested orally. Preferably in the form of beverage, ring, granule, tablet or capsule.

The health functional food of the present invention may further comprise ingredients that are conventionally added at the time of food production and which are pharmaceutically acceptable. For example, in the case of beverage, one or more components may be further added in addition to the compound of the present invention in citric acid, liquid fructose, sugar, glucose, acetic acid, malic acid, juice and the like.

The amount that can be included as an active ingredient of the health functional food according to the present invention can be appropriately selected according to the age, sex, weight, condition, and symptom of a person who desires to prevent or improve cancer, g to 10.0 g, and the health functional food having such a content may be ingested to obtain cancer prevention and improvement effects.

Hereinafter, the present invention will be described in detail with reference to Examples and Experimental Examples.

It should be noted, however, that the following examples and experimental examples are illustrative of the present invention, and the present invention is not limited to the following examples and experimental examples.

< Example  1> MELK shRNA  making

<1-1> MELK  And primer  Sequencing

The following experiment was carried out for the production of MELK shRNA.

Specifically, the MELK sequence (SEQ ID NO: 1) was provided through Pubmed ( http://www.ncbi.nlm.nih.gov/pubmed/ ) (Accession number BC014039) (Fig. 1). The sequence was input to the invitrogen homepage (https://rnaidesigner.lifetechnologies.com/rnaiexpress/) and 15 sequence candidates (SEQ ID NOS: 2 to 16) expected to be capable of knockdown cadidate) (Table 1). Subsequently, the papers were examined to determine the sequence of shRNAs currently used for MELK1 deficiency (Table 2).

No start
(Start) Sequence Region 1 (SEQ ID NO: 2) 210 GGTCAAACTTGCCTGCCATAT ORF 2 (SEQ ID NO: 3) 2376 GCTCTTAACTATGTCTCTTTG 3-UTR 3 (SEQ ID NO: 4) 870 GCAGGTGGACCCAAAGAAA ORF 4 (SEQ ID NO: 5) 923 GGATCATGCAAGATTACAACT ORF 5 (SEQ ID NO: 6) 1656 GGAATTGGATCTCAACCAAGC ORF 6 (SEQ ID NO: 7) 1662 GGATCTCAACCAAGCACATAT ORF 7 (SEQ ID NO: 8) 2118 GGATGAGTGTGGGTGTGATAC 3-UTR 8 (SEQ ID NO: 9) 723 GGGCATACTGTTATATGTT ORF 9 (SEQ ID NO: 10) 2279 GCCCATCTGTCATTATGTTAC 3-UTR 10 (SEQ ID NO: 11) 831 GCTCTCTCCCAGTAGCATTCT ORF 11 (SEQ ID NO: 12) 2129 GGTGTGATACAGCCTACATAA 3-UTR 12 (SEQ ID NO: 13) 719 GCATGGGCATACTGTTATATG ORF 13 (SEQ ID NO: 14) 1074 CCTCACGGCTACCTATCTT ORF 14 (SEQ ID NO: 15) 1032 GCAAACAATGGAGGATTTA ORF 15 (SEQ ID NO: 16) 1123 CCAGTTCGTTTAAGGCTTT ORF

                          Sequence MELK1 AACCCAAGGGTAACAAGGA MELK2 CAGGCAAACAATGGAGGAT MELK3 AAAAACCCGATGTGGTGGGTA

<1-2> MELK  Deficient shRNA  Production and verification

The following experiment was carried out to construct shRNA having the sequence of [Table 1].

Specifically, one forward and one reverse primer described in SEQ ID NOS: 16 to 46 required for the production of each of the shRNAs was ordered and supplied (Macrogen) (Table 3). 100 pmole / [mu] l concentration of forward primer and reverse primer annealing. The primer sequences for preparing conventional MELK shRNAs are shown in Table 4.

On the other hand, the pLKO.1 vector purchased from Addgene was cleaved with AgeI and EcoRI, and the annealed primer was cloned into a pLKO.1 vector using a ligase .

The above three vectors were transfected into 293T cells using pCMV-VSV-G (0.7 ㎍), pCMV-dR8.2 (1.3 ㎍) or pLKO.1 vector (2 ㎍) cloned with MELK shRNA After several days lentivirus was obtained from the medium in which the color (yellow) changed. The obtained medium was stored at 4 캜 for immediate use or at -70 캜 for long-term use.

number Name of the primer Sequence One sihMELKF210
(SEQ ID NO: 17) 5'-CCG GGG TCA AAC TTG CCT GCC ATA TGC TAG
CAT ATG GCA GGC AAG TTT GAC CTT TTT G-3 ' sihMELKR210
(SEQ ID NO: 18) 5'-AAT TCA AAA AGG TCA AAC TTG CCT GCC ATA
TGC TAG CAT ATG GCA GGC AAG TTT GAC C-3 ' 2 sihMELKF2376UTR
(SEQ ID NO: 19) 5'-CCG GGC TCT TAA CTA TGT CTC TTT GGC TAG
CCA AAG AGA CAT AGT TAA GAG CTT TTT G-3 ' sihMELKR2376UTR
(SEQ ID NO: 20) 5'-AAT TCA AAA AGC TCT TAA CTA TGT CTC TTT
GGC TAG CCA AAG AGA CAT AGT TAA GAG C-3 ' 3 sihMELK_F870
(SEQ ID NO: 21) 5'-CCG GGC AGG TGG ACC CAA AGA AAG CTA GCT
TTC TTT GGG TCC ACC TGC TTT TTG-3 '( sihMELK_R870
(SEQ ID NO: 22) 5'-AAT TCA AAA AGC AGG TGG ACC CAA AGA AAG
CTA GCT TTC TTT GGG TCC ACC TGC-3 ' 4 sihMELKF923
(SEQ ID NO: 23) 5'-CCG GGG ATC ATG CAA GAT TAC AAC TGC TAG
CAG TTG TAA TCT TGC ATG ATC CTT TTT G-3 ' sihMELKR923
(SEQ ID NO: 24) 5'-AAT TCA AAA AGG ATC ATG CAA GAT TAC AAC
TGC TAG CAG TTG TAA TCT TGC ATG ATC C-3 ' 5 sihMELKF1656
(SEQ ID NO: 25) 5'-CCG GGG AAT TGG ATC TCA ACC AAG CGC TAG
CGC TTG GTT GAG ATC CAA TTC CTT TTT G-3 ' sihMELKR1656
(SEQ ID NO: 26) 5'-AAT TCA AAA AGG AAT TGG ATC TCA ACC AAG
CGC TAG CGC TTG GTT GAG ATC CAA TTC C-3 ' 6 sihMELKF1662
(SEQ ID NO: 27) 5'-CCG GGG ATC TCA ACC AAG CAC ATA TGC TAG
CAT ATG TGC TTG GTT GAG ATC CTT TTT G-3 ' sihMELKR1662
(SEQ ID NO: 28) 5'-AAT TCA AAA AGG ATC TCA ACC AAG CAC ATA
TGC TAG CAT ATG TGC TTG GTT GAG ATC C-3 ' 7 sihMELKF2118UTR
(SEQ ID NO: 29) 5'-CCG GGG ATG AGT GTG GGT GTG ATA CGC TAG
CGT ATC ACA CCC ACA CTC ATC CTT TTT G-3 ' sihMELKR2118UTR
(SEQ ID NO: 30) 5'-AAT TCA AAA AGG ATG AGT GTG GGT GTG ATA
CGC TAG CGT ATC ACA CCC ACA CTC ATC C-3 ' 8 sihMELK_F723
(SEQ ID NO: 31) 5'-CCG GGG GCA TAC TGT TAT ATG TTG CTA GCA
ACA TAT AAC AGT ATG CCC TTT TTG-3 ' sihMELK_R723
(SEQ ID NO: 32) 5'-AAT TCA AAA AGG GCA TAC TGT TAT ATG TTG
CTA GCA ACA TAT AAC AGT ATG CCC-3 ' 9 sihMELKF2279UTR
(SEQ ID NO: 33) 5'-CCG GGC CCA TCT GTC ATT ATG TTA CGC TAG
CGT AAC ATA ATG ACA GAT GGG CTT TTT G-3 ' sihMELKR2279UTR
(SEQ ID NO: 34) 5'-AAT TCA AAA AGC CCA TCT GTC ATT ATG TTA
CGC TAG CGT AAC ATA ATG ACA GAT GGG C-3 ' 10 sihMELKF831
(SEQ ID NO: 35) 5'-CCG GGC TCT CTC CCA GTA GCA TTC TGC TAG
CAG AAT GCT ACT GGG AGA GAG CTT TTT G-3 ' sihMELKR831
(SEQ ID NO: 36) 5'-AAT TCA AAA AGC TCT CTC CCA GTA GCA TTC
TGC TAG CAG AAT GCT ACT GGG AGA GAG C-3 ' 11 sihMELKF2129UTR
(SEQ ID NO: 37) 5'-CCG GGG TGT GAT ACA GCC TAC ATA AGC TAG
CTT ATG TAG GCT GTA TCA CAC CTT TTT G-3 ' sihMELKR2129UTR
(SEQ ID NO: 38) 5'-AAT TCA AAA AGG TGT GAT ACA GCC TAC ATA
AGC TAG CTT ATG TAG GCT GTA TCA CAC C-3 ' 12 sihMELKF719
(SEQ ID NO: 39) 5'-CCG GGC ATG GGC ATA CTG TTA TAT GGC TAG
CCA TAT AAC AGT ATG CCC ATG CTT TTT G-3 ' sihMELKR719
(SEQ ID NO: 40) 5'-AAT TCA AAA AGC ATG GGC ATA CTG TTA TAT
GGC TAG CCA TAT AAC AGT ATG CCC ATG C-3 ' 13 sihMELK_F1074
(SEQ ID NO: 41) 5'-CCG GCC TCA CGG CTA CCT ATC TTG CTA GCA
AGA TAG GTA GTG AGG TTT TTG-3 ' sihMELK_R1074
(SEQ ID NO: 42) 5'-AAT TCA AAA ACC TCA CGG CTA CCT ATC TTG
CTA GCA AGA TAG GTA GCC GTG AGG-3 ' 14 sihMELK_F1032
(SEQ ID NO: 43) 5'-CCG GGC AAA CAA TGG AGG ATT TAG CTA GCT
AAA TCC TCC ATT GTT TGC TTT TTG-3 ' sihMELK_R1032
(SEQ ID NO: 44) 5'-AAT TCA AAA AGC AAA CAA TGG AGG ATT TAG
CTA GCT AAA TCC TCC ATT GTT TGC-3 ' 15 sihMELK_F1123
(SEQ ID NO: 45) 5'-CCG GCC AGT TCG TTT AAG GCT TTG CTA GCA
AAG CCT TAA ACG AAC TGG TTT TTG-3 ' sihMELK_R1123
(SEQ ID NO: 46) 5'-AAT TCA AAA ACC AGT TCG TTT AAG GCT TTG
CTA GCA AAG CCT TAA ACG AAC TGG-3 '

Name of the primer        Primer sequences for conventional MELK shRNA production MELK1 MELK1_F 5'-CCGG AACCCAAGGGTAACAAGGA GCTAGC tccttgttacccttgggtt TTTTTG-3 ' MELK1_R 5'-AATTCAAAAA AACCCAAGGGTAACAAGGA GCTAGC tccttgttacccttgggtt-3 ' MELK2 MELK2_F 5'-CCGG CAGGCAAACAATGGAGGAT GCTAGC atcctccattgtttgcctg TTTTTG-3 ' MELK2_R 5'-AATTCAAAAA CAGGCAAACAATGGAGGAT GCTAGC atcctccattgtttgcctg-3 ' MELK3 MELK3_F 5'-CCGG AAAAACCCGATGTGGTGGGTA GCTAGC tacccaccacatcgggttttt TTTTTG-3 ' MELK3_R 5'-AATTCAAAAA AAAAACCCGATGTGGTGGGTA GCTAGC tacccaccacatcgggttttt-3 '

< Experimental Example  1> Lentivirus  using MELK  Confirmation of expression inhibition

The following experiment was conducted to confirm that the lentivirus obtained from the vector in which the MELK shRNA was cloned was activated.

Specifically, the obtained lentivirus was infected with cervical cancer Hela cells, kidney cancer A498 cells, lung cancer A549 cells or ovarian cancer SK-OV-3 cells, respectively. 200 μl of virus soup was added to the medium of each cell. On the next day, puromycin (2 [mu] g / ml) was incubated for 3 days to select cells containing the virus (living cells). After 3 days, cell lysates were collected and subjected to electrophoresis and Western blotting. MELK antibody was used to confirm the inhibition of MELK protein expression.

As a result, as shown in FIG. 2 and FIG. 3, when 15 lentiviruses were infected with HeLa cells, the expression of MELK protein was inhibited compared to the control (Gli), and MELK1 and MELK2 , The shRNA of the present invention significantly inhibited the MELK protein (Fig. 2). In addition, when the 5th (SEQ ID NO: 6), 9 (SEQ ID NO: 10) and 12 (SEQ ID NO: 13) lentiviruses were infected to the respective A498 cells, A549 cells or SK-OV- Gli2), the expression of MELK protein was inhibited (Fig. 3).

FIG. 4 shows the results of measuring the inhibition of MELK protein expression by infecting A498 cells, A549 cells or SK-OV-3 cells with conventional MELK shRNAs (MELK1, MELK2 and MELK3) In OV-3 cells, there was almost no difference compared to the control group, and thus it was confirmed that the existing MELK shRNA had insufficient inhibitory effect (FIG. 4).

This indicates that the MELK shRNA gene of the present invention is superior to the previously known MELK shRNA in suppressing the expression. Thus, it was confirmed that the shRNA of the present invention significantly inhibited the MELK protein.

<110> Korea Research Institute of Bioscience and Biotechnology <120> Novel MELK shRNA suppressing MELK expression, and use thereof <130> 14P-10-029 <160> 46 <170> Kopatentin 2.0 <210> 1 <211> 2501 <212> DNA <213> MELK maternal embryonic leucine zipper kinase Homo sapiens, mRNA <400> 1 cgaaaagatt cttaggaacg ccgtaccagc cgcgtctctc aggacagcag gcccctgtcc 60 ttctgtcggg cgccgctcag ccgtgccctc cgcccctcag gttctttttc taattccaaa 120 taaacttgca agaggactat gaaagattat gatgaacttc tcaaatatta tgaattacat 180 gaaactattg ggacaggtgg ctttgcaaag gtcaaacttg cctgccatat ccttactgga 240 gagatggtag ctataaaaat catggataaa aacacactag ggagtgattt gccccggatc 300 aaaacggaga ttgaggcctt gaagaacctg agacatcagc atatatgtca actctaccat 360 gtgctagaga cagccaacaa aatattcatg gttcttgagt actgccctgg aggagagctg 420 tttgactata taatttccca ggatcgcctg tcagaagagg agacccgggt tgtcttccgt 480 cagatagtat ctgctgttgc ttatgtgcac agccagggct atgctcacag ggacctcaag 540 ccagaaaatt tgctgtttga tgaatatcat aaattaaagc tgattgactt tggtctctgt 600 gcaaaaccca agggtaacaa ggattaccat ctacagacat gctgtgggag tctggcttat 660 gcagcacctg agttaataca aggcaaatca tatcttggat cagaggcaga tgtttggagc 720 atgggcatac tgttatatgt tcttatgtgt ggatttctac catttgatga tgataatgta 780 atggctttat acaagaagat tatgagagga aaatatgatg ttcccaagtg gctctctccc 840 agtagcattc tgcttcttca acaaatgctg caggtggacc caaagaaacg gatttctatg 900 aaaaatctat tgaaccatcc ctggatcatg caagattaca actatcctgt tgagtggcaa 960 agcaagaatc cttttattca cctcgatgat gattgcgtaa cagaactttc tgtacatcac 1020 agaaacaaca ggcaaacaat ggaggattta atttcactgt ggcagtatga tcacctcacg 1080 gctacctatc ttctgcttct agccaagaag gctcggggaa aaccagttcg tttaaggctt 1140 tcttctttct cctgtggaca agccagtgct accccattca cagacatcaa gtcaaataat 1200 tggagtctgg aagatgtgac cgcaagtgat aaaaattatg tggcgggatt aatagactat 1260 gattggtgtg aagatgattt atcaacaggt gctgctactc cccgaacatc acagtttacc 1320 aagtactgga cagaatcaaa tggggtggaa tctaaatcat taactccagc cttatgcaga 1380 acacctgcaa ataaattaaa gaacaaagaa aatgtatata ctcctaagtc tgctgtaaag 1440 aatgaagagt actttatgtt tcctgagcca aagactccag ttaataagaa ccagcataag 1500 agagaaatac tcactacgcc aaatcgttac actacaccct caaaagctag aaaccagtgc 1560 ctgaaagaaa ctccaattaa aataccagta aattcaacag gaacagacaa gttaatgaca 1620 ggtgtcatta gccctgagag gcggtgccgc tcagtggaat tggatctcaa ccaagcacat 1680 atggaggaga ctccaaaaag aaagggagcc aaagtgtttg ggagccttga aagggggttg 1740 gataaggtta tcactgtgct caccaggagc aaaaggaagg gttctgccag agacgggccc 1800 agaagactaa agcttcacta taatgtgact acaactagat tagtgaatcc agatcaactg 1860 ttgaatgaaa taatgtctat tcttccaaag aagcatgttg actttgtaca aaagggttat 1920 acactgaagt gtcaaacaca gtcagatttt gggaaagtga caatgcaatt tgaattagaa 1980 gtgtgccagc ttcaaaaacc cgatgtggtg ggtatcagga ggcagcggct taagggcgat 2040 gcctgggttt acaaaagatt agtggaagac atcctatcta gctgcaaggt ataattgatg 2100 gattcttcca tcctgccgga tgagtgtggg tgtgatacag cctacataaa gactgttatg 2160 atcgctttga ttttaaagtt cattggaact accaacttgt ttctaaagag ctatcttaag 2220 accaatatct ctttgttttt aaacaaaaga tattattttg tgtatgaatc taaatcaagc 2280 ccatctgtca ttatgttact gtctttttta atcatgtggt tttgtatatt aataattgtt 2340 gactttctta gattcacttc catatgtgaa tgtaagctct taactatgtc tctttgtaat 2400 gtgtaatttc tttctgaaat aaaaccattt gtgaatataa aaaaaaaaaaaaaaaaaaa 2460 aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa a 2501 <210> 2 <211> 21 <212> DNA <213> MELK shRNA-210 <400> 2 ggtcaaactt gcctgccata t 21 <210> 3 <211> 21 <212> DNA <213> MELK shRNA-2376 <400> 3 gctcttaact atgtctcttt g 21 <210> 4 <211> 19 <212> DNA <213> MELK shRNA-870 <400> 4 gcaggtggac ccaaagaaa 19 <210> 5 <211> 21 <212> DNA <213> MELK shRNA-923 <400> 5 ggatcatgca agattacaac t 21 <210> 6 <211> 21 <212> DNA <213> MELK shRNA-1656 <400> 6 ggaattggat ctcaaccaag c 21 <210> 7 <211> 21 <212> DNA <213> MELK shRNA-1662 <400> 7 ggatctcaac caagcacata t 21 <210> 8 <211> 21 <212> DNA <213> MELK shRNA-2118 <400> 8 ggatgagtgt gggtgtgata c 21 <210> 9 <211> 19 <212> DNA <213> MELK shRNA-723 <400> 9 gggcatactg ttatatgtt 19 <210> 10 <211> 21 <212> DNA <213> MELK shRNA-2279 <400> 10 gcccatctgt cattatgtta c 21 <210> 11 <211> 21 <212> DNA <213> MELK shRNA-831 <400> 11 gctctctccc agtagcattc t 21 <210> 12 <211> 21 <212> DNA <213> MELK shRNA-2129 <400> 12 ggtgtgatac agcctacata a 21 <210> 13 <211> 21 <212> DNA <213> MELK shRNA-719 <400> 13 gcatgggcat actgttatat g 21 <210> 14 <211> 19 <212> DNA <213> MELK shRNA-1074 <400> 14 cctcacggct acctatctt 19 <210> 15 <211> 19 <212> DNA <213> MELK shRNA-1032 <400> 15 gcaaacaatg gaggattta 19 <210> 16 <211> 19 <212> DNA <213> MELK shRNA-1123 <400> 16 ccagttcgtt taaggcttt 19 <210> 17 <211> 58 <212> DNA <213> Artificial Sequence <220> <223> sihMELKF210 <400> 17 ccggggtcaa acttgcctgc catatgctag catatggcag gcaagtttga cctttttg 58 <210> 18 <211> 58 <212> DNA <213> Artificial Sequence <220> <223> sihMELKR210 <400> 18 aattcaaaaa ggtcaaactt gcctgccata tgctagcata tggcaggcaa gtttgacc 58 <210> 19 <211> 58 <212> DNA <213> Artificial Sequence <220> <223> sihMELKF2376UTR <400> 19 ccgggctctt aactatgtct ctttggctag ccaaagagac atagttaaga gctttttg 58 <210> 20 <211> 58 <212> DNA <213> Artificial Sequence <220> <223> sihMELKR2376UTR <400> 20 aattcaaaaa gctcttaact atgtctcttt ggctagccaa agagacatag ttaagagc 58 <210> 21 <211> 54 <212> DNA <213> Artificial Sequence <220> <223> sihMELK_F870 <400> 21 ccgggcaggt ggacccaaag aaagctagct ttctttgggt ccacctgctt tttg 54 <210> 22 <211> 54 <212> DNA <213> Artificial Sequence <220> <223> sihMELK_R870 <400> 22 aattcaaaaa gcaggtggac ccaaagaaag ctagctttct ttgggtccac ctgc 54 <210> 23 <211> 58 <212> DNA <213> Artificial Sequence <220> <223> sihMELKF923 <400> 23 ccggggatca tgcaagatta caactgctag cagttgtaat cttgcatgat cctttttg 58 <210> 24 <211> 58 <212> DNA <213> Artificial Sequence <220> <223> sihMELKR923 <400> 24 aattcaaaaa ggatcatgca agattacaac tgctagcagt tgtaatcttg catgatcc 58 <210> 25 <211> 58 <212> DNA <213> Artificial Sequence <220> <223> sihMELKF1656 <400> 25 ccggggaatt ggatctcaac caagcgctag cgcttggttg agatccaatt cctttttg 58 <210> 26 <211> 58 <212> DNA <213> Artificial Sequence <220> <223> sihMELKR1656 <400> 26 aattcaaaaa ggaattggat ctcaaccaag cgctagcgct tggttgagat ccaattcc 58 <210> 27 <211> 58 <212> DNA <213> Artificial Sequence <220> <223> sihMELKF1662 <400> 27 ccggggatct caaccaagca catatgctag catatgtgct tggttgagat cctttttg 58 <210> 28 <211> 58 <212> DNA <213> Artificial Sequence <220> <223> sihMELKR1662 <400> 28 aattcaaaaa ggatctcaac caagcacata tgctagcata tgtgcttggt tgagatcc 58 <210> 29 <211> 58 <212> DNA <213> Artificial Sequence <220> <223> sihMELKF2118UTR <400> 29 ccggggatga gtgtgggtgt gatacgctag cgtatcacac ccacactcat cctttttg 58 <210> 30 <211> 58 <212> DNA <213> Artificial Sequence <220> <223> sihMELKR2118UTR <400> 30 aattcaaaaa ggatgagtgt gggtgtgata cgctagcgta tcacacccac actcatcc 58 <210> 31 <211> 54 <212> DNA <213> Artificial Sequence <220> <223> sihMELK_F723 <400> 31 ccgggggcat actgttatat gttgctagca acatataaca gtatgccctt tttg 54 <210> 32 <211> 54 <212> DNA <213> Artificial Sequence <220> <223> sihMELK_R723 <400> 32 aattcaaaaa gggcatactg ttatatgttg ctagcaacat ataacagtat gccc 54 <210> 33 <211> 58 <212> DNA <213> Artificial Sequence <220> <223> sihMELKF2279UTR <400> 33 ccgggcccat ctgtcattat gttacgctag cgtaacataa tgacagatgg gctttttg 58 <210> 34 <211> 58 <212> DNA <213> Artificial Sequence <220> <223> sihMELKR2279UTR <400> 34 aattcaaaaa gcccatctgt cattatgtta cgctagcgta acataatgac agatgggc 58 <210> 35 <211> 58 <212> DNA <213> Artificial Sequence <220> <223> sihMELKF831 <400> 35 ccgggctctc tcccagtagc attctgctag cagaatgcta ctgggagaga gctttttg 58 <210> 36 <211> 58 <212> DNA <213> Artificial Sequence <220> <223> sihMELKR831 <400> 36 aattcaaaaa gctctctccc agtagcattc tgctagcaga atgctactgg gagagagc 58 <210> 37 <211> 58 <212> DNA <213> Artificial Sequence <220> <223> sihMELKF2129UTR <400> 37 ccggggtgtg atacagccta cataagctag cttatgtagg ctgtatcaca cctttttg 58 <210> 38 <211> 58 <212> DNA <213> Artificial Sequence <220> <223> sihMELKR2129UTR <400> 38 aattcaaaaa ggtgtgatac agcctacata agctagctta tgtaggctgt atcacacc 58 <210> 39 <211> 58 <212> DNA <213> Artificial Sequence <220> <223> sihMELKF719 <400> 39 ccgggcatgg gcatactgtt atatggctag ccatataaca gtatgcccat gctttttg 58 <210> 40 <211> 58 <212> DNA <213> Artificial Sequence <220> <223> sihMELKR719 <400> 40 aattcaaaaa gcatgggcat actgttatat ggctagccat ataacagtat gcccatgc 58 <210> 41 <211> 54 <212> DNA <213> Artificial Sequence <220> <223> sihMELK_F1074 <400> 41 ccggcctcac ggctacctat cttgctagca agataggtag ccgtgaggtt tttg 54 <210> 42 <211> 54 <212> DNA <213> Artificial Sequence <220> <223> sihMELK_R1074 <400> 42 aattcaaaaa cctcacggct acctatcttg ctagcaagat aggtagccgt gagg 54 <210> 43 <211> 54 <212> DNA <213> Artificial Sequence <220> <223> sihMELK_F1032 <400> 43 ccgggcaaac aatggaggat ttagctagct aaatcctcca ttgtttgctt tttg 54 <210> 44 <211> 54 <212> DNA <213> Artificial Sequence <220> <223> sihMELK_R1032 <400> 44 aattcaaaaa gcaaacaatg gaggatttag ctagctaaat cctccattgt ttgc 54 <210> 45 <211> 54 <212> DNA <213> Artificial Sequence <220> <223> sihMELK_F1123 <400> 45 ccggccagtt cgtttaaggc tttgctagca aagccttaaa cgaactggtt tttg 54 <210> 46 <211> 54 <212> DNA <213> Artificial Sequence <220> <223> sihMELK_R1123 <400> 46 aattcaaaaa ccagttcgtt taaggctttg ctagcaaagc cttaaacgaa ctgg 54

Claims (9)

An shRNA that inhibits the expression of MELK (Maternal Embryonic Leucine zipper Kinase) having the nucleotide sequence shown in SEQ ID NO: 2 to 16.
2. The shRNA according to claim 1, wherein the MELK is represented by SEQ ID NO: 1.
A vector comprising the shRNA of claim 1.
4. The vector according to claim 3, wherein the vector is any one selected from the group consisting of linear DNA, plasmid DNA, and recombinant virus vector.
The recombinant virus according to claim 4, wherein the recombinant virus is selected from the group consisting of an adenovirus, an adeno-associated virus, a retrovirus, a herpes simplex virus and a lentivirus . &Lt; / RTI &gt;
A pharmaceutical composition for preventing or treating cancer comprising the shRNA of claim 1 or the vector of claim 3 as an active ingredient.
The method of claim 6, wherein the cancer is selected from the group consisting of brain cancer, stomach cancer, breast cancer, colon cancer, pancreatic cancer and liver cancer, bladder cancer, breast cancer, cervical cancer, cholangiocellular carcinoma, chronic myelogenous leukemia (CML), colon cancer, endometriosis, Wherein the cancer is selected from the group consisting of liver cancer, non-small cell lung cancer (NSCLC), lymphoma, osteosarcoma, ovarian cancer, pancreatic cancer, prostate cancer, renal carcinoma and small cell lung cancer.
A health functional food for preventing or ameliorating cancer comprising the shRNA of claim 1 or the vector of claim 3 as an active ingredient.
9. The method of claim 8, wherein the cancer is selected from the group consisting of brain cancer, stomach cancer, breast cancer, colon cancer, pancreatic cancer and liver cancer, bladder cancer, breast cancer, cervical cancer, cholangiocellular carcinoma, chronic myelogenous leukemia (CML), colon cancer, endometriosis, Wherein the cancer is selected from the group consisting of liver cancer, non-small cell lung cancer (NSCLC), lymphoma, osteosarcoma, ovarian cancer, pancreatic cancer, prostate cancer, renal carcinoma and small cell lung cancer.

Images